ArticleMass spectrometry (Tokyo, Japan)2022
UV-Absorbing Ligand Capped Gold Nanoparticles for the SALDI-MS Analysis of Small Molecules.
Article in Mass spectrometry (Tokyo, Japan), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Stepwise Monitoring of Ligand Exchange on Gold Nanorods: From Cetyltrimethylammonium Bromide to Thiol-Functionalized Biocompatible Phosphorylcholine Using Matrix-Free LDI-TOF Mass Spectrometry.Mass spectrometry (Tokyo, Japan) · 2025Article
- Direct Additive Detection in Polymer Films via Platinum-Assisted SALDI Mass Spectrometry Imaging.Mass spectrometry (Tokyo, Japan) · 2024Article
- Analysis of carbohydrates and glycoconjugates by matrix-assisted laser desorption/ionization mass spectrometry: An update for 2021-2022.Mass spectrometry reviewsReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We report that modifying the surface of gold nanoparticles (Au NPs) with 2-mercaptopyridine-3-carboxylic acid (MPyCA) enhances surface-assisted laser desorption/ionization (SALDI) performance in the analysis of small molecules. The MPyCA ligand has a strong UV absorbance at the wavelengths of the typical MALDI laser at 337 nm, resulting in efficient thermal/energy transfer from the Au NPs to analytes during pulse-laser irradiation. In addition, the MPyCA ligand contains carboxylic acid and pyridine groups, providing affinity to various analytes through acid-base interactions. Irganox1010, glucose and meropenem were utilized as model analytes to evaluate SALDI performance because these molecules are generally ionized with difficulty by conventional MALDI-MS. Our results demonstrate that the MPyCA-Au NP based SALDI-MS could detect Irganox1010, glucose and meropenem with stronger ion peaks for these molecules compared to MALDI-MS using CHCA. The limit of detection (LOD) for meropenem was much lower in the case of SALDI (LOD=1 ng/mL) compared to MALDI (LOD=10 μg/mL).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.